XNYS · Healthcare · Drug Manufacturers - General
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Q1 2026 | 2.07 | 1.99 | -3.86% | $13.11B | ❌ Miss | -3.00% | +0.00% | +4.05% |
| 2026-02-04 | Q4 2025 | 2.00 | 2.03 | +1.50% | $13.34B | ✅ Beat | -0.91% | +4.68% | +4.72% |
| 2025-10-28 |
| Q3 2025 |
| 2.29 |
| 2.25 |
| -1.75% |
| $13.91B |
| ❌ Miss |
| — |
| — |
| — |
| 2025-07-17 | Q2 2025 | 2.38 | 2.42 | — | $14.05B | ➖ Inline | -0.61% | +2.57% | +8.46% |
| 2025-04-29 | Q1 2025 | 2.08 | 2.28 | +9.62% | $13.23B | ✅ Beat | +0.04% | -2.56% | -0.77% |
| 2025-01-31 | Q4 2024 | 1.79 | 1.98 | +10.61% | $13.15B | ✅ Beat | +0.73% | +1.47% | +5.63% |
| 2024-10-29 | Q3 2024 | 1.96 | 2.06 | +5.10% | $12.82B | ✅ Beat | -0.56% | -1.04% | -4.31% |
| 2024-07-18 | Q2 2024 | 1.86 | 1.97 | +5.91% | $12.51B | ✅ Beat | -1.02% | +2.53% | +8.12% |
Showing last 8 quarters.